{"id":"lpcn-1154a","safety":{"commonSideEffects":[{"rate":null,"effect":"Polycythemia"},{"rate":null,"effect":"Prostate-related adverse events"},{"rate":null,"effect":"Lipid profile changes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LPCN 1154A is designed to provide selective androgen receptor activation with tissue-specific effects, potentially offering therapeutic benefits in conditions requiring androgen replacement or androgen-dependent processes while minimizing systemic androgenic side effects. The drug is being developed as an oral formulation to improve patient compliance compared to injectable testosterone therapies.","oneSentence":"LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:45.485Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Testosterone replacement therapy in hypogonadal men"}]},"trialDetails":[{"nctId":"NCT06979544","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2025-06-16","conditions":"Depression, Postpartum, Depression, Post-Partum, Postpartum Depression (PPD)","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Brexanolone"],"phase":"phase_3","status":"active","brandName":"LPCN 1154A","genericName":"LPCN 1154A","companyName":"Lipocine Inc.","companyId":"lipocine-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues. Used for Testosterone replacement therapy in hypogonadal men.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}